The National Cancer Institute’s Nanodelivery Systems and Devices Branch has compiled the following list of funding opportunities and translational resources that may be of interest to nanotech developers. Click the link for each announcement to learn more.
- PAR 20-284 – Innovative Research in Cancer Nanotechnology (R01 Clinical Trials Not Allowed). The proposal should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. Receipt dates: November 4, 2020, May 6, 2021, November 4, 2021, May 5, 2022, November 3, 2022, May 4, 2023
- PAR 20-116 – Toward Translation of Nanotechnology Cancer Interventions (R01 Clinical Trials Not Allowed). The award is designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs. Receipt dates: November 19, 2020, May 20, 2021, November 18, 2021
Clinical/Translational Programs and Funding Opportunities:
- PAR-18-560: Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required). The FOA supports research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of NCI’s Division of Cancer Treatment and Diagnosis (DCTD). Due Standard Dates through Jan 8, 2021.
- NCI Experimental Therapeutics Program (NExT): Please note that the NExT Program is not a grant mechanism; applications with exceptional science cannot be accepted without a clear path to the clinic or potential benefit to patients. The mission of the NExT Program is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. Awardees will not necessarily receive direct funding; rather, the NCI may allocate various contract and grant resources toward the implementation and development of submitted projects. The NCI will partner with successful applicants to facilitate the milestone-driven progression of new anticancer drugs (small molecules, biologics) and imaging agents towards clinical evaluation and registration. See application instructions.
Basic/Applied Science Programs and Funding Opportunities:
- PAR-19-363: Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional). This FOA supports the integration of imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer treatment to determine the optimal use of these modalities in the characterization of therapy response or detecting the emergence of resistance. Due Standard Dates through May 8, 2021.
- RFA-CA-19-049/050: Revision Applications for Mechanism of Drug Resistance (R01 Clinical Trial Not Allowed/U01 Clinical Trials Not Allowed). These Moonshot RFAs support the addition of new aims and directions to ongoing NCI-funded research projects on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level. Remaining Due Dates: October 22, 2020 and June 23, 2021.
- PAR-19-156/157: Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed/U01 Clinical Trials Required). These FOAs intend to accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. Due Standard Dates through Jan 8, 2022.
- PA-19-112/111: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional, R21 Clinical Trial Optional). This FOA encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. Due Standard Dates through Jan 8, 2022.
- The Innovative Molecular Analysis Technologies (IMAT) Program: The IMAT RFAs encourage applications from individuals and groups interested in developing novel technologies suitable for the molecular analysis of cancers and their host environment in support of basic, clinical, and epidemiological research. There are multiple active FOAs under the IMAT Program, see here.
Team Science Funding Opportunities
- PAR-20-077: National Cancer Institute Program Project Applications (P01 Clinical Trial Optional). The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective. Due Standard Dates through May 2023.
- PAR-20-155: Academic-Industrial Partnerships to Translate and Validate in vivo Imaging Systems (R01 Clinical Trial Optional). Similar to PAR-18-530, this FOA intends to stimulate translations of scientific discoveries and engineering developments in imaging data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease. Due Standard Dates through September 8, 2022.
- PAR-18-530: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 Clinical Trial Optional). This FOA intends to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and manage disease. Due Standard Dates through Jan 8, 2021.